Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bunji Sato is active.

Publication


Featured researches published by Bunji Sato.


The Journal of Antibiotics | 2005

FR177391, a new anti-hyperlipidemic agent from Serratia. I. Taxonomy, fermentation, isolation, physico-chemical properties, structure elucidation and biological activities.

Bunji Sato; Hidenori Nakajima; Takashi Fujita; Shigehiro Takase; Seiji Yoshimura; Takayoshi Kinoshita; Hiroshi Terano

In the course of screening for a new anti-hyperlipidemic agent from microbial products, we found that FR177391, produced by Serratia liquefaciens No. 1821, alleviated the decrease in lipid droplet formation in differentiated 3T3-L1 adipocyte cells, induced by the addition of tumor necrosis factor-α. Structural elucidation by spectroscopic methods and X-ray crystallographic analysis of its propylamide derivative revealed that FR177391 was a chlorinated macrocyclic lactone.


Bioorganic & Medicinal Chemistry Letters | 2001

FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties

Akihiko Fujie; Toshiro Iwamoto; Bunji Sato; Hideyuki Muramatsu; Chiyoshi Kasahara; Takahisa Furuta; Yasuhiro Hori; Motohiro Hino; Seiji Hashimoto

The synthesis and biological properties of a novel water-soluble echinocandin-like lipopeptide, FR131535, are described. This compound displayed potent in vitro and in vivo antifungal activities. The hemolytic activity of FR901379 was reduced by replacing the acyl side chain. This compound showed good water-solubility, comparable to the natural product FR901379.


The Journal of Antibiotics | 2009

Discovery of anti-varicella zoster virus activity of polyether antibiotic CP-44161

Yukiko Yamagishi; Chihoko Ueno; Akemi Kato; Hirohito Kai; Hiromi Sasamura; Motoi Ueno; Bunji Sato; Akihiko Fujie; Takashi Fujii; Motohiro Hino; Eisaku Tsujii

In search for new anti-varicella zoster virus (VZV) compounds with new mechanism of action, we applied a DNA hybridization assay (dot blot method) for screening. Using this method, we screened microbial products and found the polyether compound CP-44161 from the culture broth of an actinomycete strain. CP-44161 was previously reported as an anticoccidal agent, but there has been no claim of its antiviral activities. CP-44161 showed strong anti-VZV activity against pOka strain by plaque reduction assay. Moreover, CP-44161 showed lower cytotoxicity than other antiviral polyethers, such as monensin and nigericin. Its better safety margin and strong anti-VZV properties make it a good candidate for a new anti-VZV agent.


The Journal of Antibiotics | 2009

Anti-herpes virus activity of polyether antibiotic CP-44161 in vivo

Yukiko Yamagishi; Motoi Ueno; Chihoko Ueno; Akemi Kato; Ryuichi Kanasaki; Bunji Sato; Koji Takakura; Akihiko Fujie; Hidenori Nakajima; Takashi Fujii; Motohiro Hino; Eisaku Tsujii

In the previous study, we discovered a polyether antibiotic CP-44161, which was reported earlier as an anticoccidal agent, as an anti-varicella zoster virus compound. In this study, we demonstrated that CP-44161 had a very strong and broad anti-herpes virus activities against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. To determine the antiviral activity of CP-44161 in vivo, we examined its effect on the cutaneous HSV-2 infection model in Balb/c mice. CP-44161 showed inhibitory effect on lesion development as well as acyclovir (ACV) when the treatment was started from day 3. Meanwhile, in case the start of treatment was delayed until day 4, when ACV was no longer effective, the effectiveness of CP-44161 still remained. In this model, CP-44161 also showed inhibitory effect on the proliferation of HSV-2 DNA in dorsal root ganglia. This is the first article to report that polyether antibiotics can be effective on viral infection in vivo.


The Journal of Antibiotics | 1996

New Antitumor Substances, FR901463, FR901464 and FR901465

Hidenori Nakajima; Bunji Sato; Takashi Fujita; Shigehiro Takase; Hiroshi Terano; Masakuni Okuhara


The Journal of Antibiotics | 2000

A new antimitotic substance, FR182877. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities.

Bunji Sato; Hideyuki Muramatsu; Michiyo Miyauchi; Yasuhiro Hori; Shigehiro Takase; Motohiro Hino; Seiji Hashimoto; Hiroshi Terano


The Journal of Antibiotics | 2000

A new antimitotic substance, FR182877. II. The mechanism of action.

Bunji Sato; Hidenori Nakajima; Yasuhiro Hori; Motohiro Hino; Seiji Hashimoto; Hiroshi Terano


The Journal of Antibiotics | 2000

A new antimitotic substance, FR182877. III. Structure determination

Seiji Yoshimura; Bunji Sato; Takayoshi Kinoshita; Shigehiro Takase; Hiroshi Terano


The Journal of Antibiotics | 2004

FR182876, a New Microtubule Modulator with High Water-solubility, from a Streptomyces

Seiji Yoshimura; Bunji Sato; Shigehiro Takase; Hiroshi Terano


The Journal of Antibiotics | 2004

FR901512, a Novel HMG-CoA Reductase Inhibitor Produced by an Agonomycetous Fungus No. 14919

Hidetaka Hatori; Bunji Sato; Ikuko Sato; Toshihiro Shibata; Yasuhisa Tsurumi; Kazutoshi Sakamoto; Shigehiro Takase; Hirotsugu Ueda; Motohiro Hino; Takashi Fujii

Collaboration


Dive into the Bunji Sato's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Seiji Hashimoto

Toyama Prefectural University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge